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Background: Validated Internet-based screening tools for cannabis use and abuse are needed. The present study
aimed to establish equivalence between the previously validated Alcohol, Smoking and Substance Involvement
Screening Test (ASSIST) as a paper-and-pencil (PaP)-administered questionnaire and its online use.
Methods: Two groups of cannabis users took part in this study and the results were analyzed using structural
equation modeling. One group consisted of 150 participants and was assessed with the ASSIST PaP questionnaire
in a face-to-face interview (the PaP group). They were recruited from three settings: a primary health care outpatient
clinic, a general psychiatric facility, and an ambulatory specialized addiction treatment facility. The other group (the
Web group) comprised 1382 persons who answered the online version of the same questionnaire. This sample was
drawn from people who naturalistically visited a website dedicated to helping people with cannabis addiction.
Results: The internal consistency was good for the online questionnaire (0.74) and high for the already validated
PaP questionnaire (0.91). The Web group, however, had higher scores on cannabis use than did the PaP group. The
results show support for configural invariance, meaning that the one-factor structure was preserved across groups,
although measurement equivalence between these two survey modes was not achieved. However, when the Web
group was split into two random subsamples, measurement invariance was demonstrated between them by
cross-validation.
Conclusions: Measurement equivalence was not achieved between the two survey modes. Nonetheless,
subanalyses of the Web group demonstrated that the cannabis screening questions of the ASSIST can be used for
online screening. Differences in ASSIST scores between samples may be due to the sensitive nature of the
information surveyed, with possible underreporting in face-to-face interviews, or to the different characteristics of
the Web group because of the specialized nature of the website.
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The Internet has come to be widely used as a tool for
drug treatment and research. For instance, the Web is
now commonly used in searches for medical and
psychological information [1-3]. Furthermore, different
forms of online treatments have been studied for vari-
ous mental health and addiction-related conditions
[4-6]. In consequence, an increased number of medical
and psychological studies have been performed by using
Web-based questionnaires [7], including topics related
to substance use [8].
Internet-based surveys have a number of advantages in
comparison with paper-and-pencil (PaP) questionnaires
[7,9-11], such as easy data collection and a reduction
in data entry errors. The wide dissemination of online
surveys may also lead to an increase in recruitment
and lower desirability bias compared with traditional
methods of data collection. The latter is of particular
interest for surveys on stigmatizing topics such as drug
use [7]. For example, Web-based, self-administered
questionnaires lead to higher reporting rates of sub-
stance use in adolescents compared with the rates re-
ported from PaP self-administered questionnaires [12].
Furthermore, the quality of the data provided by
Internet-based surveys on topics such as smoking [13]
and alcohol use [14] have equal or even better reliability
in Web-based questionnaires than in PaP or face-to-face
approaches. The Internet, probably because of the per-
ception that it offers anonymity, has also been found to
be a useful tool in reaching stigmatized populations,
such as illicit drug users and those who use party drugs
such as ecstasy or cannabis [15]. The feasibility of using
online research for substance use and illegal substance
use has been demonstrated in several studies [15].
Despite the wide dissemination of Internet-based sur-
veys, participants in such studies may differ from the
general population. In particular, they may be more
educated or more likely to be employed [16,17]. Never-
theless, if the possible limitations are acknowledged,
Internet-based surveys are suitable for research on topics
related to substance use and addictive behaviors, in par-
ticular to generate hypotheses that can later be tested in
more representative samples [15].
Regardless of the number of opportunities linked to on-
line research, however, some concerns remain regarding
the reliability (whereby a given procedure produces the
same results in tests repeated with the same empirical or
equivalent tools) [18] and validity of the data (the degree
to which a given procedure operationalizes the intended
concept) [18] obtained via online questionnaires [7]. Stud-
ies investigating the invariance of Web-based question-
naires and PaP surveys have demonstrated inconsistent
findings. Some studies found no major differences be-
tween the two delivery modes [19], whereas others foundvariations related to particular scales [20] and still others
reported differences between online and offline versions
of the same tests in terms of score distributions achieved
and psychometric properties of the tests [20,21]. The latter
findings are particularly true for studies related to self-
disclosure of sensitive information [22]. Social desirabil-
ity may affect answers in face-to-face interviews [23].
For instance, reports of alcohol use and sexually risky
behaviors were more likely to be fully disclosed in Web
surveys than in traditional formats [24]. Also note-
worthy is the possible impact of different designs on
the outcomes in these studies. Some researchers used
within-subjects designs, whereas others used between-
subjects designs in which the online questionnaire or
the PaP form was randomly administered, or not ad-
ministered, to the participants [25].
While an increased number of instruments classically
used for mental health assessments have been developed
and validated for Internet use [26-29], such develop-
ments are needed for the study of addictive disorders,
especially for frequently used substances such as canna-
bis [30-33]. In the last few years, international efforts
have been made to develop and validate screening as-
sessment tools related to cannabis use [34]. In particular,
after the success of the Alcohol Use Disorder Identifica-
tion Test (AUDIT) [35], efforts were made to offer simi-
lar screening tools for other substance use, including
cannabis. The Alcohol, Smoking and Substance Involve-
ment Screening Test (ASSIST) [36,37] was developed by
the World Health Organization to screen for problem-
atic or risky substance use (http://www.who.int/substan-
ce_abuse/activities/assist/en/index.html). The ASSIST
instrument was validated as a face-to-face questionnaire
in different populations and in a number of linguistic
versions, in which it was found to have sound psycho-
metric properties. Its internal consistency, assessed
with Cronbach’s α, ranged from 0.74 to 0.93. Concur-
rent validity was demonstrated by significant correla-
tions between ASSIST scores and scores from the
Addiction Severity Index [38], AUDIT [35], Revised
Fagerstrom Tolerance Questionnaire [39], and Mini
International Neuropsychiatric Interview (MINI-Plus)
[40] for the diagnosis of substance abuse or depend-
ence. Moreover, the ASSIST yielded interesting sensi-
tivity and specificity values for discrimination between
substance use and abuse and between substance abuse
and dependence [37,41-44]. In its current version
(V3.0), the ASSIST comprises eight questions for each
of the following substances: tobacco, alcohol, cannabis,
cocaine, amphetamine-type stimulants, inhalants, seda-
tives, hallucinogens, opiates, and other drugs. Question
1 deals with the lifetime use of each substance. If a sub-
stance is used, people are invited to answer additional
questions related to this specific substance.
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results; therefore, measurement equivalence of Web-
based and PaP surveys cannot be taken for granted and
must be empirically demonstrated [45,46]. To our know-
ledge, the ASSIST, despite the possibility of its use in
naturalistic online settings, has not yet been used in
Internet studies and has yet to be validated for online
studies.
In the current study, we aimed to do the following:
1. Describe the distribution of self-reported cannabis
use in two samples of cannabis users: visitors to a
cannabis prevention website who answered an online
questionnaire, and patients of three clinics who
answered a PaP questionnaire in a face-to-face
interview. Both groups answered the ASSIST version
3.0 questionnaire.
2. Analyze whether the items in the ASSIST
instrument operate equivalently across Internet and
PaP groups for gathering sensitive information (i.e.,
is the measurement model group invariant?).
Methods
Participants and procedures
We obtained two groups of cannabis users. The first
group was assessed with the ASSIST PaP questionnaire
on a face-to-face basis, and the second group answered
an online version of the same questionnaire.
The first group
The first group consisted of the adults who took part in
a previous study related to the validation of the French
version of the ASSIST questionnaire [44]. It included
150 participants, of whom 50 were patients from a pri-
mary health care outpatient clinic, 50 were outpatients
from a general psychiatric facility, and 50 were patients
from an ambulatory specialized addiction treatment fa-
cility. The use of tobacco, alcohol, and illicit substances
(cannabis, cocaine, opiates, etc.) was assessed. The three
settings were concerned with these substances, except
for the primary care setting, where cocaine and opiates
were not identified as problematic. Opiate dependence
was found in 7.3% of the sample, alcohol abuse or de-
pendence in 43.3%, and cannabis use in 85.3%. Of the
latter, 6.3% were considered to have cannabis abuse or
dependence. The mean age of the participants was 41 ±
11.5 years. They were mainly men (64%), single (76.7%),
and not working (68.5%). All participants treated in
these settings were eligible if they were older than
18 years, able to speak in French, and able to give their
written informed consent.
The ASSIST (PaP) assessment (in French) was made
during an interview with a trained psychologist or
psychiatrist who completed the ASSIST during theinterview. The ethics committee of the Geneva Univer-
sity Hospitals approved the study.
The second group
The second group was drawn from people who natural-
istically visited (without specific advertisement or invi-
tation) a French-language website dedicated to online
cannabis help (stop-cannabis.ch). The website offers
information and online help for cannabis users. In par-
ticular, visitors may access a number of automated in-
terventions such as an online motivational interview, a
brief intervention (computer-tailored feedback based
on the ASSIST scores), and support for cannabis cessa-
tion in a text-messaging format. Although the website
is primarily dedicated to people asking for information
or help related to cannabis use, it is accessible to any-
one, and no specific registration is required to use it. It
also includes information for the relatives of cannabis
users. The website has been visited by 676,000 Internet
users since 2008. No special advertising strategies pro-
mote the website: It is mostly accessed via keyword
search on general search engines such as Google, as
well as from links on other websites such as a sister
website dedicated to tobacco smokers. Participants
could answer the ASSIST questions related to cannabis
use online without any registration procedure and with-
out answering additional socio-demographic questions.
After answering the questionnaire (in French), partici-
pants received, on a new Web page, a personalized,
computer-tailored feedback report based on their an-
swers (one graph and 250 words) that commented on
their cannabis use and recommended treatment if ne-
cessary. We did not collect any demographic informa-
tion about participants. Answers emerging from the
same IP address were excluded. Participants had the
option to accept or decline storage of their answers for
survey purposes.
Measurements
After a positive screening result on lifetime substance
use of cannabis (ASSIST, Question1), both groups of
participants answered the following questions:
Questions 2 to 7 of the ASSIST:
Q2: In the past three months how often have you used
cannabis?
Q3: During the past three months how often have you
had a strong desire or urge to use cannabis?
Q4: During the past three months how often has your
use of cannabis led to health, social, legal or
financial problems?
Q5: During the past three months how often have you
failed to do what was normally expected of you
because of your use of cannabis?
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expressed concern about your use of cannabis?
Q7: Have you ever tried to control, cut down or stop
using cannabis?
Questions 2 to 5 are rated on a 5-point Likert scale
ranging from “never” (in the past 3 months) to “daily or
almost daily”, whereas Questions 6 and 7 use a three-
category rating (“no never”, “yes in the past 3 months”,
“yes but not in the past 3 months”). The total score, cal-
culated as the sum of scores received for Questions 2
through 7 inclusive, is bound to measure one latent fac-
tor: the specific substance involvement score as defined
by the ASSIST, here the cannabis involvement score.
This score enabled us to identify three groups of can-
nabis users:
– Low risk (score: 0–3): The participant is at low risk
of health and other problems from his/her current
pattern of use.
– Moderate risk (score: 4–26): The participant is at
risk of health and other problems from his/her
current pattern of substance use.
– High risk (score ≥ 27): The participant is at high risk
of experiencing severe problems (health, social,
financial, legal, relationship) as a result of his/her
current pattern of use and is likely to be dependent.
Statistical analyses
SPSS 18.0 (Statistical Package for the Social Sciences,
SPSS Inc., Chicago, IL) and AMOS 19.0 (Analysis of
Moment Structures; SPSS Inc., Chicago, IL) software
programs were used to perform the statistical analyses.
The distribution of self-reported cannabis use was com-
pared by type of survey using χ2 tests.
We next assessed internal consistency of the subscale
in the Web survey by Cronbach's alpha coefficient.
Ideally, α should be above 0.70, but not much higher
than 0.90 [47].
For the multigroup invariance hypothesis, we used the
structural equation modeling (SEM) procedure described
by Jöreskog [48]. Depending on the research question,
searching for group equivalence may imply a series of
tests performed in the following restrictive order: config-
ural equivalence, measurement equivalence, and struc-
tural equivalence. Configural invariance testing focused
on the extent to which the number of factors and the
pattern of their structure are similar between groups. In
testing for measurement and structural invariance, we
focused more specifically on the extent to which param-
eters in the measurement and structural components of
the model are equivalent across groups [49-51]. It is
worth noting, however, that the determination of an ap-
propriate baseline model is required for each groupseparately, from which the configural model is derived.
Given that one of our research questions concerns
measurement equivalence across groups, statistical ana-
lyses focus on configural invariance and measurement
invariance.
Evaluation of model fit
A model’s goodness of fit is examined through various
indices, as described below [52-54]:
a. The χ2 to degrees of freedom ratio (χ2/df )
b. The comparative fit index (CFI)
c. The root mean square error of approximation
(RMSEA)
Changes in goodness-of-fit statistics were also exam-
ined to detect differences in the models. A significant
difference in χ2 values between nested models means
that all equality constraints do not hold across the
groups. Since the variables are measured on an ordinal
scale with relatively few categories and the values be-
tween categories are not equidistant, asymptotically
distribution-free estimation instead of maximum likeli-
hood estimation was used here as one of the strategies
to accommodate non-normally distributed data.
Sample size considerations
Sample size plays an important role in providing un-
biased parameter estimates and accurate model fit infor-
mation. Bentler and Chou [55] recommended a ratio of
at least 5:1 of subjects to variables for normal and ellip-
tical distributions, and there seems to be a general con-
sensus among researchers to adopt this ratio. However,
for categorical or non-normally distributed variables, as
is the case here, larger samples are required than for
continuous or normally distributed variables. A ratio of
at least 10 subjects per variable for this type of distribu-
tion is recommended [55,56]. The sample in the current
study fulfills this requirement.
Results
A sample of 1382 persons participated in the Web study,
whereas 150 persons filled in the PaP questionnaire. In
the Web survey, 1% of the participants were excluded
because of missing data, leaving a sample size of 1366
for the analysis. There were no missing data in the PaP
survey.
Cannabis use
There were statistically significant differences between
the two groups for all ASSIST questions (Table 1). Par-
ticipants from the Web survey scored higher on all
items.
Table 1 Self-reported cannabis use by group and
questionnaire format (expressed in %), using Questions 2
to 7 of the ASSIST V3.0 questionnaire
Question Format χ2 p
Outpatients
PaP (n = 150)
Web
(n = 1366)
2. In the past three
months how often have
you used cannabis?
830.2 <0.0005
- Never 75.3 2.5
- One or two times 3.3 3.9
- Monthly 5.3 4.2
- Weekly 6.0 15.4
- Daily or almost daily 10.0 74.0
3. During the past three
months how often have
you had a strong desire
or urge to use cannabis?
381. 9 <0.0005
- Never 78.0 12.3
- One or two times 4.0 14.0
- Monthly 2.7 5.3
- Weekly 6.7 18.4
- Daily or almost daily 8.7 50.1
4. During the past three
months how often has
your use of cannabis led
to health, social, legal or
financial problems?
110.9 <0.0005
- Never 88.6 45.0
- One or two times 3.4 21.2
- Monthly 2.0 13.3
- Weekly 2.7 11.8
- Daily or almost daily 3.4 8.7
5. During the past three
months how often have
you failed to do what
was normally expected
of you because of your
use of cannabis?
168.7 <0.0005
- Never 96.0 40.5
- One or two times 0 22.3
- Monthly 0.7 10.9
- Weekly 2.7 15.6
- Daily or almost daily 0.7 10.8
6. Has a friend or relative
or anyone else ever
expressed concern
about your use of
cannabis?
147. 8 <0.0005
- No, never 60.2 35.3
- Yes, in the past three
months
9.3 17.2
- Yes, but not in the past
three months
6.0 47.5
Table 1 Self-reported cannabis use by group and
questionnaire format (expressed in %), using Questions 2
to 7 of the ASSIST V3.0 questionnaire (Continued)
7. Have you ever tried to
control, cut down or
stop using cannabis?
157.7 <0.0005
- No, never 88.7 35.3
- Yes, in the past three
months
5.3 25.8




score (sum of responses
to Q2-Q7)
4.2 (8.7) 22.8 (9.9) −24.3* <0.0005
Risk level according to
ASSIST v3.0
874.3 <0.0005
- Low (0–3) 77.3 3.3
- Moderate (4–26) 18.7 54.2
- High (≥27) 4.0 42.5
*Obtained by t-test.
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According to the validation study of the French version of
the ASSIST, the internal consistency of the cannabis in-
volvement scale yielded a Cronbach’s alpha coefficient of
0.91 [44]. In the current study, these coefficients were 0.91
and 0.74 for the PaP and the Web surveys, respectively.
Testing for configural equivalence
As noted earlier, a prerequisite to testing for instrument
equivalence is to establish a well-fitting model for each
group separately, followed by a combined baseline
model in which the same parameters are estimated
again within the framework of a multigroup model. Re-
sults showed no misspecification for the PaP model,
whereas possible misspecifications regarding two error
terms (Items 2 and 3, 3 and 7) were highlighted for the
Web model. It was subsequently respecified and reesti-
mated with these two error covariances included. These
baseline models were considered optimal in represent-
ing the data for the PaP sample (χ2/df = 1.93; CFI =
0.90; RMSEA = 0.08) and for the Web sample (χ2/df =
1.97; CFI = 0.99; RMSEA = 0.03).
Next, these differentially specified baseline models
were incorporated into one file for the purposes of test-
ing cross-group equivalence. Assessment of this model
revealed a good fit to the data, as indicated by the CFI
(0.99) and RMSEA (0.02). The χ2 value (8.06, df = 6)
provides the baseline value against which all subse-
quent tests for invariance are compared (Table 2).
Testing for measurement equivalence
A model with loadings constrained to be equal across
groups had a fit that was significantly poorer than that
Table 2 Summary of goodness-of-fit statistics for tests of invariance across format types (PaP and web format)
Model description RMSEA CFI χ2 df Δχ2 Δdf Statistical significance
1. Configural model: no constraints imposed 0.02 0.99 8.06 6 - - -
2. Factor loadings: constrained equally across groups 0.03 0.97 45.44 19 37.38 13 p < 0.0005
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0.03). As can be seen from Table 2, the χ2 difference
value between the constrained model and the configural
model is statistically significant. This finding suggests
that the constrained model is significantly worse than
the unconstrained model and argues for nonequivalence
of factor loadings across the groups. In other words, the
hypothesis that the PaP survey and the Web survey have
the same factor means is rejected. The factor loadings by
type of format are displayed in Table 3.Testing for invariance across two random subsamples of
the Web sample
From the results reported above, the equivalence of the
online and the offline versions of the ASSIST has not
been demonstrated. To check whether the ASSIST could
be used in online studies, we randomly split the Web
sample into two comparable subgroups from the per-
spective of the ASSIST risk level (Table 4). We then ap-
plied the SEM methodology described earlier to the first
subsample and cross-validated the results by using the
other subsample in a multigroup analysis.
The baseline results showed good model fit for Sub-
sample 1 (χ2/df = 1.77; CFI = 0.99; RMSEA = 0.03), as
well as for Subsample 2 (χ2/df = 2.06; CFI = 0.99;
RMSEA = 0.04). The next step consisted in establishing
configural invariance for both groups together without
constraint: it also yielded satisfactory results. As can be
seen in Table 5, configural invariance (Model 1) is sup-
ported, indicating that the one-factor structure in each
group is preserved. From Model 2 to Model 4, all suc-
cessive invariance tests (metric invariance, residual vari-
ance invariance, strict factorial invariance) held, given
the nonsignificant difference in the χ2 values (Table 5).Table 3 Factor loadings by format type
Question
Q2: In the past three months how often have you used cannabis?
Q3: During the past three months how often have you had a strong desire o
Q4: During the past three months how often has your use of cannabis led to
Q5: During the past three months how often have you failed to do what wa
your use of cannabis?
Q6: Has a friend or relative or anyone else ever expressed concern about you
Q7: Have you ever tried to control, cut down or stop using cannabis?Discussion
In this study, the internal consistency and the validity of
the ASSIST (for the assessment of cannabis use) were
compared in two samples: visitors of a cannabis preven-
tion website who answered an online survey in French,
and outpatients of three clinics in Switzerland who an-
swered an ASSIST PaP questionnaire. The internal
consistency was high for the PaP survey and good for
the Web survey (0.91 and 0.74, respectively). A possible
explanation for this difference in value is that Cronbach’s
alpha is sensitive to deviations from normality. There-
fore, if the data do not meet the assumptions of normal-
ity and linearity, as in the Web sample, the reliability
may be underestimated by the current formulas used for
the calculation of this value [57]. Regarding validity, the
results show that the study supports configural invari-
ance, meaning that the one-factor structure is preserved
across groups.
Measurement invariance was not supported by the
study results, however. Cannabis use was more frequent
and problematic for the Web group than it was for the
clinic-recruited sample. Only 10% of the PaP sample re-
ported daily use of cannabis in the past 3 months, in
comparison to 74% of the Web sample (Question 2). As
shown in Table 1, very few PaP participants (4%) admit-
ted to having failed in tasks normally expected from
them because of their cannabis use (Question 4),
whereas 60% of the Web sample endorsed this item.
Consequently, the loading of this item in the factor ana-
lysis (Table 3) was very different across groups. The
same problem applies to Question 7 (tried to stop or cut
down).
These results may be explained, in part, by the absence
of a randomization procedure (on the PaP and total





r urge to use cannabis? 0.98 0.62
health, social, legal or financial problems? 0.76 0.71
s normally expected of you because of 0.24 0.67
r use of cannabis? 0.46 0.44
0.22 0.50
Table 4 Self-reported cannabis use by random subsample (expressed in %), using the cannabis-related questions of
the ASSIST V3.0 questionnaire







2. In the past three months how often have you used cannabis? 1.0
- Never 2.5 2.5 2.5
- One or two times 3.9 3.9 3.9
- Monthly 4.2 4.1 4.3
- Weekly 15.4 16.0 14.8
- Daily or almost daily 74.0 73.5 74.5
3. During the past three months how often have you had a strong
desire or urge to use cannabis?
0.6
- Never 12.3 12.6 12.2
- One or two times 14.0 15.3 12.6
- Monthly 5.3 5.3 4.9
- Weekly 18.4 17.9 18.8
- Daily or almost daily 50.1 48.9 51.5
4. During the past three months how often has your use of cannabis
led to health, social, legal or financial problems?
0.8
- Never 45.0 44.4 45.7
- One or two times 21.2 22.4 19.8
- Monthly 13.3 13.2 13.5
- Weekly 11.8 11.3 12.3
- Daily or almost daily 8.7 8.7 8.7
5. During the past three months how often have you failed to do
what was normally expected of you because of your use of cannabis?
0.8
- Never 40.5 41.5 39.4
- One or two times 22.3 21.0 23.7
- Monthly 10.9 10.8 11.1
- Weekly 15.6 15.7 15.2
- Daily or almost daily 10.8 11.0 10.6
6. Has a friend or relative or anyone else ever expressed concern
about your use of cannabis?
0.3
- No, never 35.3 34.2 36.0
- Yes, in the past three months 17.2 16.1 18.2
- Yes, but not in the past three months 47.5 49.6 45.7
7. Have you ever tried to control, cut down or stop using cannabis? 0.7
- No, never 35.3 36.0 35.2
- Yes, in the past three months 25.8 24.7 26.8
- Yes, but not in the past three months 38.9 39.3 38.1
Cannabis involvement score (sum of responses to Q2-Q7) 22.8 (9.9) 22.8 (9.8) 22.8 (10.0) 1.0
Risk level according to ASSIST v3.0 0.9
- Low (0–3) 3.3 3.1 3.6
- Moderate (4–26) 54.2 53.8 53.8
- High (≥27) 42.5 43.1 42.5
p-Values resulting from comparison of Subsample 1 and Subsample 2.
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Table 5 Summary of goodness-of-fit statistics for invariance tests across the two random subsamples
Model description RMSEA CFI χ2 df χ2/df Δχ2 Δdf Statistical significance
1. Configural invariance: no constraints imposed 0.03 0.99 26.80 14 1.9 - - -
2. Factor loadings: constrained equally across groups 0.02 0.99 32.31 19 1.7 5.51 5 p = 0.4
3. Factor loadings and variances: constrained equally 0.02 0.99 32.33 20 1.6 5.53 6 p = 0.5
4. Factor loadings, variances, and error covariances: constrained
equally
0.02 0.99 38.76 28 1.4 11.97 14 p = 0.6
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the Web sample (from the naturalistic visitors of a web-
site dedicated to helping people facing cannabis addic-
tion) are probably explained by the involvement (via
self-selection) of participants who were more concerned
by their cannabis use than would be the case in the gen-
eral population, as suggested by another study on the
self-selection bias associated with online studies [59].
The participants from the stop-cannabis.ch website se-
lected themselves to visit the website and chose to assess
their cannabis use with the ASSIST, probably in relation
to concerns about their cannabis consumption. The par-
ticipants from the clinic centers, in contrast, may not
have been preoccupied by their cannabis use [44].
The contribution of a desirability bias to the differ-
ences observed between the PaP and the Web group
should also not be ignored. This bias was previously re-
ported in face-to-face interviews [7]. The phenomenon
leads to underreporting of stigmatized behaviors (i.e.
cannabis use) in face-to-face settings in comparison to
that in computerized self-assessments [60,61]. Further-
more, differences in the understanding of some ques-
tions cannot be fully ruled out [7,58].Study limitations and strengths
This study has several limitations, the most important of
which is that we did not include randomly equivalent
groups by type of survey. This limitation may have under-
mined external validity. It further highlights selection [59]
and desirability biases [45,62], hence restricting the statis-
tical comparison of the PaP and the Web groups to a de-
scriptive level. Another limitation is a lack of other clinical
assessments. Comparison with a diagnostic instrument,
for instance, would allow us to calculate the sensitivity
and the specificity of the Internet-administered ASSIST,
two inextricably linked measures that help clinicians in
deciding whether to rule a diagnosis in or out. A third
limitation is that detailed socio-demographic characteris-
tics of the Internet sample were not available to examine
the profile of the respondents.
These limitations having been acknowledged, the study
nonetheless has two major strengths. The first is that,
owing to the large Web-sample size, it has been possible toanalyze two randomly selected groups whose measurement
equivalence results support the view that the ASSIST is a
valid instrument in Web surveys.
The second strength that must be highlighted is that,
although some studies have been performed on the on-
line assessment of substance use [63] or on Internet-
based prevention [64] or treatment [65,66] of cannabis
use, our study is, to the best of our knowledge, the first
to describe cannabis use of naturalistically self-selected
users of a specialized website. This is an important
addition, demonstrating the acceptability of such web-
sites in naturalistic settings by cannabis users who are
concerned with their behavior.
Conclusions
Despite the limitations, it appears that the cannabis
screening questions of the ASSIST instrument are useful
in a Web-based format. The instrument could be used for
screening and then possibly for online prevention and
intervention. Further studies using the ASSIST for the as-
sessment of other addictions, in other populations, or
under different conditions while using the same statistical
designs (e.g. random within-subjects, between-subjects
designs) are warranted to generalize these findings.
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